147 related articles for article (PubMed ID: 20663207)
1. APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.
Pettilä V; Kyhälä L; Kylänpää ML; Leppäniemi A; Tallgren M; Markkola A; Puolakkainen P; Repo H; Kemppainen E
Crit Care; 2010; 14(4):R139. PubMed ID: 20663207
[TBL] [Abstract][Full Text] [Related]
2. Activated protein C in severe acute pancreatitis without sepsis? Not just yet ..
Shankar-Hari M; Wyncoll D
Crit Care; 2010; 14(4):188. PubMed ID: 20707935
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C retards recovery from coagulopathy in severe acute pancreatitis.
Kyhälä L; Lindström O; Kylänpää L; Mustonen H; Puolakkainen P; Kemppainen E; Tallgren M; Pettilä V; Repo H; Petäjä J
Scand J Clin Lab Invest; 2016; 76(1):10-6. PubMed ID: 26403265
[TBL] [Abstract][Full Text] [Related]
4. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.
Johnson CD; Kingsnorth AN; Imrie CW; McMahon MJ; Neoptolemos JP; McKay C; Toh SK; Skaife P; Leeder PC; Wilson P; Larvin M; Curtis LD
Gut; 2001 Jan; 48(1):62-9. PubMed ID: 11115824
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
6. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
[TBL] [Abstract][Full Text] [Related]
7. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial.
Fowler AA; Truwit JD; Hite RD; Morris PE; DeWilde C; Priday A; Fisher B; Thacker LR; Natarajan R; Brophy DF; Sculthorpe R; Nanchal R; Syed A; Sturgill J; Martin GS; Sevransky J; Kashiouris M; Hamman S; Egan KF; Hastings A; Spencer W; Tench S; Mehkri O; Bindas J; Duggal A; Graf J; Zellner S; Yanny L; McPolin C; Hollrith T; Kramer D; Ojielo C; Damm T; Cassity E; Wieliczko A; Halquist M
JAMA; 2019 Oct; 322(13):1261-1270. PubMed ID: 31573637
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP) protocol and statistical analysis plan: a prospective, multicentre, double-blind, randomized, placebo controlled clinical trial.
Vine J; Berlin N; Moskowitz A; Berg KM; Liu X; Balaji L; Donnino MW; Grossestreuer AV
Contemp Clin Trials; 2024 Apr; 139():107486. PubMed ID: 38431131
[TBL] [Abstract][Full Text] [Related]
9. Intravenous omega-3 fatty acids are associated with better clinical outcome and less inflammation in patients with predicted severe acute pancreatitis: A randomised double blind controlled trial.
Al-Leswas D; Eltweri AM; Chung WY; Arshad A; Stephenson JA; Al-Taan O; Pollard C; Fisk HL; Calder PC; Garcea G; Metcalfe MS; Dennison AR
Clin Nutr; 2020 Sep; 39(9):2711-2719. PubMed ID: 32921364
[TBL] [Abstract][Full Text] [Related]
10. Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial.
Miranda CJ; Mason JM; Babu BI; Sheen AJ; Eddleston JM; Parker MJ; Pemberton P; Siriwardena AK
Pancreatology; 2015; 15(6):635-41. PubMed ID: 26547592
[TBL] [Abstract][Full Text] [Related]
11. AGI grade-guided chaiqin chengqi decoction treatment for predicted moderately severe and severe acute pancreatitis (CAP trial): study protocol of a randomised, double-blind, placebo-controlled, parallel-group, pragmatic clinical trial.
Chen Z; Yang X; Guo J; Jin T; Lin Z; Zhu P; Li J; Li L; Sun X; Du D; Jiang K; He Y; Cai F; Li L; Hu C; Tan Q; Huang W; Deng L; Xia Q
Trials; 2022 Nov; 23(1):933. PubMed ID: 36348365
[TBL] [Abstract][Full Text] [Related]
12. Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.
Dempfle CE; Elmas E; Link A; Suvajac N; Liebe V; Janes J; Borggrefe M
Crit Care; 2011; 15(1):R23. PubMed ID: 21241489
[TBL] [Abstract][Full Text] [Related]
13. Multiple organ dysfunction associated with severe acute pancreatitis.
Halonen KI; Pettilä V; Leppäniemi AK; Kemppainen EA; Puolakkainen PA; Haapiainen RK
Crit Care Med; 2002 Jun; 30(6):1274-9. PubMed ID: 12072681
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial.
Cornet AD; Groeneveld AB; Hofstra JJ; Vlaar AP; Tuinman PR; van Lingen A; Levi M; Girbes AR; Schultz MJ; Beishuizen A
PLoS One; 2014; 9(3):e90983. PubMed ID: 24632673
[TBL] [Abstract][Full Text] [Related]
15. Intestinal bacterial overgrowth in the early stage of severe acute pancreatitis is associated with acute respiratory distress syndrome.
Liang XY; Jia TX; Zhang M
World J Gastroenterol; 2021 Apr; 27(15):1643-1654. PubMed ID: 33958849
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis.
Abraham P; Rodriques J; Moulick N; Dharap S; Chafekar N; Verma PK; Agrawal A; Prabhakar B; Basavaraj A; Shah A; Chaphekar AP; Biswal UC; Malhan ST; Bakshi G
J Assoc Physicians India; 2013 Aug; 61(8):535-8. PubMed ID: 24818336
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial of activated protein C for the treatment of acute lung injury.
Liu KD; Levitt J; Zhuo H; Kallet RH; Brady S; Steingrub J; Tidswell M; Siegel MD; Soto G; Peterson MW; Chesnutt MS; Phillips C; Weinacker A; Thompson BT; Eisner MD; Matthay MA
Am J Respir Crit Care Med; 2008 Sep; 178(6):618-23. PubMed ID: 18565951
[TBL] [Abstract][Full Text] [Related]
18. Early angiopoietin-2 levels after onset predict the advent of severe pancreatitis, multiple organ failure, and infectious complications in patients with acute pancreatitis.
Buddingh KT; Koudstaal LG; van Santvoort HC; Besselink MG; Timmer R; Rosman C; van Goor H; Nijmeijer RM; Gooszen H; Leuvenink HG; Ploeg RJ; Nieuwenhuijs VB
J Am Coll Surg; 2014 Jan; 218(1):26-32. PubMed ID: 24355874
[TBL] [Abstract][Full Text] [Related]
19. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
[TBL] [Abstract][Full Text] [Related]
20. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.
Abraham E; Baughman R; Fletcher E; Heard S; Lamberti J; Levy H; Nelson L; Rumbak M; Steingrub J; Taylor J; Park YC; Hynds JM; Freitag J
Crit Care Med; 1999 Aug; 27(8):1478-85. PubMed ID: 10470753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
